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LETTERS
Original Antigenic 
Sin and Pandemic 
(H1N1) 2009
To the Editor: While pandemic 
(H1N1) 2009 was in its earliest stages, 
age distribution data indicated surpris-
ingly few cases among persons >65 
years of age. The initial assumption 
was that few persons >65 years of 
age had yet to be exposed. However, 
as more data became available from 
Mexico, Australia, and the United 
States, the age distribution pattern 
persisted (1).
This observation raised the ques-
tion about whether older persons were 
protected from infection with an inﬂ  u-
enza virus A (H1N1) strain acquired 
many years ago. Indeed, data from 
the Centers for Disease Control and 
Prevention showed that approximate-
ly two thirds of older persons have 
evidence of immunity to pandemic 
(H1N1) 2009 virus. In 1960, Thomas 
Francis proposed the hypothesis of 
original antigenic sin, a phenomenon 
whereby a person who as a child was 
ﬁ  rst exposed to a speciﬁ  c inﬂ  uenza vi-
rus A would, throughout life, mount an 
immune response to the virus of child-
hood, even when exposed to other 
antigenically dissimilar inﬂ  uenza vi-
ruses. In effect, the original antibody 
response generated by the immune 
system against a speciﬁ  c  inﬂ  uenza 
viral strain was hypothesized to have 
colored all future responses to inﬂ  u-
enza (2).
Serologic responses of humans 
and other mammals have supported 
this theory. A new hemagglutinin (HA) 
subtype emerged in 1918 that was re-
sponsible for the pandemic that year. 
Through 1956, the strain evolved, ac-
cumulating mutations. In an era before 
inﬂ  uenza viruses were subtyped was 
performed, the original 1918 inﬂ  uenza 
virus A (H1N1) was dubbed a swine 
strain, whereas the virus of the 1930s 
was known as inﬂ  uenza A. However, 
the amount of drift accrued by 1947 
was enough to render the seasonal 
vaccine of the time ineffective, and the 
new drifted virus strain was named A′. 
Throughout the period, the virus con-
tinued to be the subtype H1N1, as it is 
now designated.
In 1956, Davenport and Hennessy 
examined the antibody responses of 3 
different age cohorts, each of which 
received different monovalent inﬂ  u-
enza vaccines prepared with vaccine 
strains circulating at different earlier 
periods (3) (Table). Prevaccination se-
rum samples conﬁ  rmed the presence 
of antibodies speciﬁ  c to the inﬂ  uenza 
virus that circulated during each re-
spective cohort’s childhood.
Each of the 3 monovalent vac-
cines was administered to a group 
from each age cohort. Vaccination 
directed toward inﬂ  uenza strains dis-
tinct from the virus of childhood not 
only resulted in development of im-
munity to the vaccine strain but also 
boosted the immune response to the 
virus strain that circulated during each 
person’s childhood, i.e., original an-
tigenic sin was apparent in each age 
cohort. Several other studies with hu-
mans, ferrets, rats, and rabbits yielded 
similar results (4,5).
Evidence from more recent stud-
ies largely supported the veracity of 
original antigenic sin. In a 1976 study, 
persons were vaccinated with a virus 
that circulated in 1973, an antigeni-
cally drifted variant of the 1968 inﬂ  u-
enza virus A (H3N2), and the response 
was assessed. As in earlier studies, ex-
amination of the antibodies generated 
indicated that the vaccine-induced 
antibodies were not only to the 1973 
variant it contained but also to the vi-
rus that had circulated earlier. As the 
hypothesis postulates, the vaccine-
induced antibodies to the 1968 strain 
were more numerous than those to the 
actual vaccine strain (6). Results from 
a 1984 experiment that used cell cul-
tures with donor lymphocytes were 
similar (7). A 1994 study found that 
current vaccine strains induced anti-
bodies to the inﬂ  uenza virus circulat-
ing during the childhood of persons 
in each age cohort (8). An additional 
study, published in 2009, conﬁ  rmed 
the presence of antigenic sin in mice 
and showed a greater tendency for 
live-virus vaccines to produce the phe-
nomenon (9).
One recent study is at variance 
with the others. It showed that mono-
clonal antibodies generated through 
vaccination were highly speciﬁ  c to the 
current vaccine strain rather than to 
inﬂ  uenza strains that had circulated in 
the past (10).
At the advent of the 2009 pan-
demic, fears of a severe pandemic were 
rampant. However, any prior immuni-
ty that was present in the population 
would dampen the impact of the virus. 
Early reports conﬁ  rmed that the virus 
was less common in groups of older 
adults. Vaccine recommendations for 
certain age groups were developed ac-
cording to that pattern of illness.
Because inﬂ  uenza virus A (H1N1) 
circulated continually after 1918 until 
1957, most persons born before 1957 
had been infected primarily with sub-
type H1N1. According to the theory of 
original antigenic sin, these persons 
may have partial protection from se-
vere disease from infection with the 
new inﬂ   uenza virus A (H1N1), i.e., 
pandemic (H1N1) 2009. Supporting 
this hypothesis is the paucity of infec-
tions in Mexico from persons now in 
their 50s and 60s and few reports in 
the United States or Australia of cases 
in this age group (1). This fact should 
inform policy decisions and merits 
further immunologic consideration. 
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Table. Influenza strains dominant for specific age cohorts from 1956 study* 
Age cohort, y  Influenza strain 
4–10 (born 1946–1952)  Aƍ
17–28 (born 1928–1939)  A
>30 (born <1926)  Swine
*Adapted from (3). LETTERS
Inﬂ  uenza surge planning is premised 
on a high incidence of illness among 
elderly persons, but if the current pat-
tern of illness continues, healthcare 
facilities also should prepare to treat 
younger persons who may constitute 
the bulk of cases. Additionally, stud-
ies of persons born during 1957–1968
should be conducted to quantify anti-
body levels to pandemic (H1N1) 2009 
virus, focusing on the degree of preex-
isting immunity that may have existed 
and was boosted by prior encounters 
with subtype H1N1 viruses
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Swine Inﬂ  uenza A 
Vaccines, 
Pandemic (H1N1) 
2009 Virus, and 
Cross-Reactivity
To the Editor: Since its ﬁ  rst 
emergence in the human population in 
spring 2009 (1–3) infections with pan-
demic (H1N1) 2009 virus have been 
reported in pigs, turkeys, and some 
carnivore species (4,5). The pandemic 
(H1N1) 2009 virus can be experimen-
tally transmitted between pigs (6). 
The reported transmissibility of the 
virus raises the question as to whether 
authorized swine inﬂ  uenza  vaccine 
strains may be cross-reactive to pan-
demic (H1N1) 2009 virus. Kyriakis et 
al. (7) investigated the cross-reactivity 
of 66 pig serum samples from differ-
ent infection and vaccination trials and 
reported cross-reactions between the 
avian-like H1N1 viruses circulating in 
the European pig population (avH1N1) 
and the classical swine H1N1 viruses 
(cH1N1) with pandemic (H1N1) 2009 
virus by hemagglutination inhibition 
assay. 
To investigate this cross-reactivity 
in more detail, a neutralization test was 
applied in the study we report here. A 
serial dilution of serum samples was 
prepared (log4). All virus strains were 
adjusted to 100 ﬁ  fty-percent  tissue 
culture infectious doses. This work-
ing dilution of virus was mixed with 
serum dilutions and incubated 1 hour 
at 37°C. Madin-Darby bovine kid-
ney monolayers were infected with 
the neutralization mixtures. After 48 
hours of incubation, cells were ﬁ  xed 
with acetone (4°C–8°C) and investi-
gated by indirect immunoﬂ  uorescent 
assay. Finally, the 50% neutralization 
titer was calculated.
Hyperimmune serum samples 
were established by using a 4-fold vac-
cination of pigs with antigens of H1N1 
vaccine strains (A/New Jersey/8/1976, 
A/sw/Netherlands/25/1980, A/sw/
IDT/Re230/1992, A/sw/Haselünne/
IDT2617/2003), and a strain of 
pandemic (H1N1) 2009 virus (A/
Hamburg/7/2009) by using Freund ad-
juvant. Blood samples were taken 14 
days after last immunization. A vac-
cine containing the pandemic (H1N1) 
2009 virus was produced. Swine in-
ﬂ  uenza vaccines available in central 
Europe and the newly produced vac-
cine containing pandemic (H1N1) 
2009 virus (A/Hamburg/7/2009) were 
administered to pigs (2-fold vaccina-
tion with 1–2 mL of the vaccine 21–28 
days apart intramuscularly). Blood 
was withdrawn 7 days after second 
administration.
In addition, an experimental aero-
sol infection was conducted by using 
the parental strain of the most recent 
avH1N1 strain contained in a Euro-
pean swine inﬂ  uenza vaccine (A/sw/
Haselünne/IDT2617/2003). Blood 
samples were taken 10 days after in-
fection.
The investigation of the hyper-
immune serum samples detected 
neutralizing activity between the 
pandemic (H1N1) 2009 virus and 
European avH1N1 vaccine strains 
(A/sw/Netherlands/25/1980, A/sw/
IDT/Re230/1992, A/sw/Haselünne/
IDT2617/2003), as well as with the 
cH1N1 strain A/New Jersey/8/1976 
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